Published in Oncotarget on September 27, 2016
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Estimating the world cancer burden: Globocan 2000. Int J Cancer (2001) 16.92
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin (2014) 11.09
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell (1994) 8.90
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene (1995) 3.96
Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Science (1987) 2.17
Molecular biology of lung cancer. J Thorac Dis (2013) 1.67
Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum (2010) 1.67
Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev (2004) 1.65
Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med (2010) 1.34
Two distinct tumor suppressor loci within chromosome 11p15 implicated in breast cancer progression and metastasis. Hum Mol Genet (1998) 1.25
Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics. Int J Biol Sci (2014) 1.16
Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res (1995) 1.13
p21Cip1 and p27Kip1 induce distinct cell cycle effects and differentiation programs in myeloid leukemia cells. J Biol Chem (2005) 1.06
p53 expression overcomes p21WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells. Oncogene (1997) 0.96
MiR-449c targets c-Myc and inhibits NSCLC cell progression. FEBS Lett (2013) 0.93
The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc. Proc Natl Acad Sci U S A (2015) 0.93
Candidate tumour suppressor CCDC19 regulates miR-184 direct targeting of C-Myc thereby suppressing cell growth in non-small cell lung cancers. J Cell Mol Med (2014) 0.91
Epidemiology of Lung Cancer. Adv Exp Med Biol (2016) 0.91
Identification of PHRF1 as a tumor suppressor that promotes the TGF-β cytostatic program through selective release of TGIF-driven PML inactivation. Cell Rep (2013) 0.84
TGIF1 promoted the growth and migration of cancer cells in nonsmall cell lung cancer. Tumour Biol (2015) 0.81
Elevated expression of TGIF is involved in lung carcinogenesis. Tumour Biol (2015) 0.80
Disruption of the PHRF1 Tumor Suppressor Network by PML-RARα Drives Acute Promyelocytic Leukemia Pathogenesis. Cell Rep (2015) 0.79
PHRF1 promotes genome integrity by modulating non-homologous end-joining. Cell Death Dis (2015) 0.77
Chest wall hamartoma with Wiedemann-Beckwith syndrome: clinical report and brief review of chromosome 11p15.5-related tumors. Am J Med Genet (2001) 0.77
A cumulative meta-analysis on the association of toll-like receptor 4 gene Asp299Gly polymorphism with cancer risk. Eur J Cancer (2016) 1.07
HER3 over-expression and overall survival in gastrointestinal cancers. Oncotarget (2015) 0.76
The association of GSTM1 deletion polymorphism with lung cancer risk in Chinese population: evidence from an updated meta-analysis. Sci Rep (2015) 0.76
Elevated expression of STIM1 is involved in lung tumorigenesis. Oncotarget (2016) 0.75
Overexpression of SIRT6 attenuates the tumorigenicity of hepatocellular carcinoma cells. Oncotarget (2017) 0.75
Note of clarification of data on the association between CYP2E1 RsaI polymorphism and lung cancer risk. Eur J Cancer (2015) 0.75